Compare AFG & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFG | EXAS |
|---|---|---|
| Founded | 1872 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 11.0B |
| IPO Year | N/A | N/A |
| Metric | AFG | EXAS |
|---|---|---|
| Price | $132.49 | $101.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 20 |
| Target Price | ★ $131.00 | $76.38 |
| AVG Volume (30 Days) | 433.2K | ★ 10.3M |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.52 | N/A |
| Revenue | ★ $8,011,000,000.00 | $3,082,033,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $4.91 | $13.51 |
| P/E Ratio | $13.92 | ★ N/A |
| Revenue Growth | 1.20 | ★ 14.47 |
| 52 Week Low | $114.73 | $38.81 |
| 52 Week High | $150.02 | $101.87 |
| Indicator | AFG | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 89.74 |
| Support Level | $130.00 | $100.98 |
| Resistance Level | $138.75 | $101.43 |
| Average True Range (ATR) | 2.61 | 2.25 |
| MACD | -0.76 | 0.53 |
| Stochastic Oscillator | 22.57 | 97.74 |
American Financial Group Inc is a holding company that is engaged in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. The Company operates through two segments: Property & Casualty Insurance and Other. The Property & Casualty segment includes Property & Transportation, covering buses, trucks, marine, agriculture, and commercial property; Specialty Casualty, offering excess & surplus, liability, and professional insurance; and Specialty Financial, providing risk management for lending and leasing institutions, fidelity and surety products, and trade credit insurance. The company's insurance operations are conducted through the Great American Insurance Group.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.